New gene therapy to treat tau-related brain diseases
Development of a novel gene therapy for the treatment of tauopathy
This study is testing a new gene therapy that uses special molecules to lower harmful tau proteins in the brain, which could help people with Alzheimer's and frontotemporal dementia feel better and slow down their symptoms.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-10526133 on NIH RePORTER |
What this research studies
This research focuses on developing a novel gene therapy using DNAzymes to target and reduce the levels of tau proteins associated with neurodegenerative diseases like Alzheimer's and frontotemporal dementia. The approach aims to cross the blood-brain barrier effectively, allowing for systemic delivery without the need for invasive procedures. By cleaving the mRNA transcripts of tau proteins, this therapy seeks to slow down or prevent the progression of these debilitating conditions. Patients participating in this research may receive a treatment that could significantly alter the course of their disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tauopathies, particularly those with Alzheimer's disease or frontotemporal dementia.
Not a fit: Patients with tauopathies not caused by tau protein abnormalities or those with other unrelated neurodegenerative diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option that slows or prevents the progression of tauopathies, improving cognitive function and quality of life for patients.
How similar studies have performed: While the use of DNAzymes is a relatively novel approach, preliminary studies in other conditions have shown promise, suggesting potential for success in treating tauopathies.
Where this research is happening
Memphis, United States
- University of Tennessee Health Sci Ctr — Memphis, United States (Active)
Researchers
- Principal investigator: Khan, Mohammad Moshahid — University of Tennessee Health Sci Ctr
- Study coordinator: Khan, Mohammad Moshahid
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.